CBD Shows Promise Against One of the World's Most Drug-Resistant Bacteria
CBD demonstrated antimicrobial activity against extensively drug-resistant Acinetobacter baumannii and synergized with antibiotics, reducing their needed concentrations by up to 1,000-fold.
Quick Facts
What This Study Found
CBD synergized with gentamicin, meropenem, and colistin against XDR A. baumannii, reducing effective antibiotic concentrations up to 1,000-fold. CBD caused rapid concentration-dependent killing through extensive membrane damage, confirmed by electron microscopy.
Key Numbers
26 XDR A. baumannii isolates from ICU devices. CBD MIC: 3.9 to >500 µg/mL. Synergy with gentamicin, meropenem, colistin reduced effective concentrations up to 1,000-fold. Complete bacterial clearance at 4× MIC within 2 hours.
How They Did This
In vitro study testing CBD against 26 XDR A. baumannii ICU isolates using MIC/MBC determination, checkerboard synergy assays, biofilm inhibition/eradication, time-kill studies, membrane integrity assays, and scanning electron microscopy.
Why This Research Matters
Extensively drug-resistant bacteria are a global health crisis. CBD's ability to synergize with existing antibiotics — potentially making them effective again at much lower doses — represents a novel approach to antimicrobial resistance.
The Bigger Picture
The antimicrobial resistance crisis needs novel approaches. CBD's membrane-disrupting mechanism is fundamentally different from conventional antibiotics, making cross-resistance unlikely and combination therapy a promising strategy.
What This Study Doesn't Tell Us
In vitro study only — achievable tissue concentrations of CBD may limit in vivo effectiveness. MIC range was very wide (3.9-500+ µg/mL), suggesting variable effectiveness. No animal infection model tested.
Questions This Raises
- ?Can CBD concentrations sufficient for antibacterial synergy be achieved in patients?
- ?Would topical CBD-antibiotic combinations be feasible for wound infections?
Trust & Context
- Key Stat:
- Evidence Grade:
- Comprehensive in vitro characterization with multiple complementary assays, but no animal model validation limits clinical translation.
- Study Age:
- Recent study adding to growing evidence of CBD's antimicrobial potential, particularly relevant as antibiotic resistance intensifies globally.
- Original Title:
- Potential of Cannabidiol (CBD) to overcome extensively drug-resistant Acinetobacter baumannii.
- Published In:
- BMC complementary medicine and therapies, 25(1), 308 (2025)
- Authors:
- Yosboonruang, Atchariya, Kiddee, Anong, Siriphap, Achiraya, Pook-In, Grissana, Suwancharoen, Chittakun, Duangjai, Acharaporn, Praphasawat, Ratsada, Reuk-Ngam, Nanthawan, Nawong, Siriwan, Rawangkan, Anchalee
- Database ID:
- RTHC-08006
Evidence Hierarchy
Frequently Asked Questions
Can CBD fight antibiotic-resistant bacteria?
In lab studies, yes — CBD killed extensively drug-resistant A. baumannii and made existing antibiotics effective again at much lower doses. Clinical application would require further research.
How does CBD kill bacteria?
CBD disrupts bacterial cell membranes, causing them to leak their contents. This mechanism is fundamentally different from conventional antibiotics, making cross-resistance unlikely.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-antibiotics-safe-cannabis-while-on
Cite This Study
https://rethinkthc.com/research/RTHC-08006APA
Yosboonruang, Atchariya; Kiddee, Anong; Siriphap, Achiraya; Pook-In, Grissana; Suwancharoen, Chittakun; Duangjai, Acharaporn; Praphasawat, Ratsada; Reuk-Ngam, Nanthawan; Nawong, Siriwan; Rawangkan, Anchalee. (2025). Potential of Cannabidiol (CBD) to overcome extensively drug-resistant Acinetobacter baumannii.. BMC complementary medicine and therapies, 25(1), 308. https://doi.org/10.1186/s12906-025-05056-w
MLA
Yosboonruang, Atchariya, et al. "Potential of Cannabidiol (CBD) to overcome extensively drug-resistant Acinetobacter baumannii.." BMC complementary medicine and therapies, 2025. https://doi.org/10.1186/s12906-025-05056-w
RethinkTHC
RethinkTHC Research Database. "Potential of Cannabidiol (CBD) to overcome extensively drug-..." RTHC-08006. Retrieved from https://rethinkthc.com/research/yosboonruang-2025-potential-of-cannabidiol-cbd
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.